Deadline: 15-Sep-2026
Pfizer is seeking proposals for projects that improve vaccination environments to prevent respiratory infectious diseases among older adults and high-risk individuals in Japan. The grant focuses on smoother vaccine access, risk communication, vaccine hesitancy, and practical vaccination approaches tailored to the living environments of vulnerable populations.
Eligible organizations in Japan may apply for individual project funding of up to 7,500,000 JPY. The program supports healthcare improvement initiatives related to respiratory infectious diseases such as COVID-19, pneumococcal disease, and RSV infection.
What is the Pfizer Vaccination Environment Grant?
The Pfizer grant titled “Improving the Vaccination Environment to Prevent Respiratory Infectious Diseases in Older Adults and High-Risk Individuals” supports healthcare improvement projects in Japan.
The grant aims to strengthen vaccination environments for people who are at higher risk of severe respiratory infectious diseases.
The program supports practical initiatives that improve access, communication, education, and delivery models for vaccination.
Main Purpose of the Grant
The main purpose of the grant is to help older adults and high-risk individuals receive appropriate vaccination more smoothly and confidently.
The program aims to:
- Improve vaccination access environments
- Support risk communication related to vaccination
- Address vaccine hesitancy
- Strengthen communication techniques that promote vaccination
- Develop vaccination approaches suited to older adults and high-risk groups
- Improve prevention of respiratory infectious diseases
- Support healthcare improvement in Japan
Geographic Focus
The program focuses on Japan.
Eligible applicants must be organizations in Japan that can legally receive award funding directly from Pfizer International LLC.
Funding Amount
Individual projects requesting up to 7,500,000 JPY will be considered.
Applicants should prepare a realistic budget that supports the proposed healthcare improvement activities, collaboration model, communication work, and implementation plan.
Who is Eligible?
Applications are open to eligible organizations in Japan.
Eligible applicants may include:
- Medical professional schools
- Dental professional schools
- Nursing professional schools
- Allied health professional schools
- Pharmacy professional schools
- Healthcare institutions
- Professional organizations
- Government agencies
- Other entities with a mission related to healthcare improvement
Applicants must apply through an organization that is legally able to receive funding directly from Pfizer International LLC.
Project Lead Requirement
The Project Lead, Principal Investigator, or an authorized designee must represent the requesting organization.
This person should have an appropriate role in managing the proposed initiative.
The requesting organization must maintain a key role in the project, even when the project involves collaboration with other partners.
Target Beneficiaries
The program focuses on older adults and high-risk individuals in Japan.
Target beneficiaries may include:
- Older adults
- People at higher risk of respiratory infectious diseases
- Individuals living in settings where vaccination access is difficult
- Patients vulnerable to COVID-19, pneumococcal disease, or RSV infection
- Healthcare providers supporting vaccination decisions
- Communities affected by vaccine hesitancy or access barriers
Respiratory Infectious Diseases Covered
The program focuses on vaccination approaches related to respiratory infectious diseases.
These may include:
- COVID-19
- Pneumococcal disease
- RSV infection
- Other relevant respiratory infectious disease prevention areas linked to vaccination
Key Focus Areas
The grant supports projects that improve vaccination access, communication, and confidence.
Key focus areas include:
- Vaccination environment improvement
- Vaccine access
- Older adult health
- High-risk individuals
- Respiratory infectious disease prevention
- Risk communication
- Vaccine hesitancy
- Communication education
- Healthcare improvement
- COVID-19 prevention
- Pneumococcal disease prevention
- RSV prevention
- Tailored vaccination approaches
What Types of Projects Are Supported?
Eligible projects should focus on improving vaccination environments and supporting effective vaccination approaches.
Supported project activities may include:
- Establishing smoother vaccination access systems
- Improving vaccination pathways for older adults
- Developing communication education for healthcare professionals
- Addressing vaccine hesitancy among high-risk groups
- Improving risk communication around vaccination
- Creating vaccination approaches suited to living environments
- Supporting collaboration across healthcare teams or institutions
- Testing practical models for vaccination support
- Strengthening healthcare improvement practices related to respiratory disease prevention
Vaccination Access Environment
A vaccination access environment refers to the systems, settings, and processes that make it easier for people to receive vaccines.
Projects may address barriers such as:
- Difficulty reaching vaccination sites
- Lack of clear information
- Limited coordination between care providers
- Low awareness of vaccine benefits
- Communication gaps with older adults or caregivers
- Challenges linked to living arrangements or care settings
Risk Communication and Vaccine Hesitancy
The program supports education and communication strategies that help people understand vaccination risks, benefits, and disease prevention.
Risk communication may include:
- Clear explanation of respiratory infection risks
- Communication about vaccine benefits and limitations
- Addressing misinformation or uncertainty
- Building trust between healthcare providers and patients
- Improving provider-patient communication
- Helping older adults and high-risk individuals make informed decisions
Tailored Vaccination Approaches
Projects should consider the living environment and real-life needs of older adults and high-risk individuals.
Tailored approaches may include strategies for:
- Community-based settings
- Long-term care environments
- Home-based support
- Healthcare facility coordination
- Caregiver involvement
- Patient education
- Outreach to high-risk groups
- Integrated healthcare team communication
Collaboration Opportunities
Collaborations are encouraged where all partners have a relevant role.
Projects may involve collaboration:
- Within the same institution
- Between departments
- Across professional teams
- Among different institutions
- Between healthcare organizations and professional groups
- With public or community-facing health agencies
The requesting organization must maintain a key role in the project.
Pfizer Internal Review Process
The competitive grant program supports healthcare improvement initiatives through the Pfizer Internal Review Process.
Applications will be reviewed to determine their alignment with the program’s purpose, eligibility requirements, healthcare improvement goals, and potential impact.
Key Concepts Explained
Vaccination Environment
A vaccination environment includes the access systems, communication methods, healthcare settings, workflows, and support structures that influence whether people can receive vaccination smoothly.
High-Risk Individuals
High-risk individuals are people who may face greater risk of severe illness from respiratory infectious diseases due to age, health status, underlying conditions, or living environment.
Risk Communication
Risk communication is the clear, accurate, and trusted sharing of information about health risks, prevention options, and decision-making.
Vaccine Hesitancy
Vaccine hesitancy refers to delay, uncertainty, or refusal of vaccination despite availability of vaccines.
Healthcare Improvement
Healthcare improvement refers to organized efforts to improve the quality, access, safety, effectiveness, or outcomes of healthcare services.
How the Grant Works
Applicants submit proposals through an eligible organization in Japan.
The proposed project should focus on improving vaccination environments for older adults and high-risk individuals.
Projects should clearly explain the target population, vaccination challenge, intervention approach, collaboration model, budget, and expected healthcare improvement outcomes.
How to Apply
Applicants should prepare a proposal that demonstrates clear healthcare improvement value and alignment with the program’s vaccination priorities.
Suggested Application Steps
- Confirm that the applicant organization is based in Japan.
- Confirm that the organization can legally receive funding from Pfizer International LLC.
- Identify the respiratory infectious disease vaccination challenge.
- Define the target population, such as older adults or high-risk individuals.
- Explain the access, communication, or hesitancy barrier being addressed.
- Develop a practical intervention to improve vaccination environments.
- Identify partners and clarify their roles where collaboration is included.
- Ensure the requesting organization maintains a key role in the project.
- Prepare a project budget of up to 7,500,000 JPY.
- Identify the Project Lead, Principal Investigator, or authorized designee.
- Submit the proposal according to Pfizer’s application requirements.
Assessment Considerations
Applications should demonstrate strong alignment with healthcare improvement and vaccination environment goals.
Review may consider:
- Eligibility of the requesting organization
- Relevance to Japan
- Focus on older adults or high-risk individuals
- Alignment with respiratory infectious disease prevention
- Strength of the vaccination access approach
- Quality of risk communication or vaccine hesitancy strategy
- Feasibility of the project plan
- Role of collaborators and professional teams
- Organizational capacity
- Potential for measurable healthcare improvement
- Budget clarity and appropriateness
Expected Results
Funded projects should help improve vaccination access, confidence, and implementation.
Expected results may include:
- Improved vaccination access for older adults
- Better communication about vaccination risks and benefits
- Reduced vaccine hesitancy
- Stronger healthcare provider communication skills
- Vaccination approaches adapted to living environments
- Better coordination among healthcare teams or institutions
- Improved prevention of respiratory infectious diseases
- Stronger healthcare improvement models in Japan
Why It Matters
Older adults and high-risk individuals may face serious health risks from respiratory infectious diseases.
Vaccination can help reduce severe illness, but access barriers, communication gaps, and vaccine hesitancy can prevent people from receiving timely protection.
This Pfizer grant supports healthcare improvement projects that make vaccination easier, clearer, and more responsive to the needs of vulnerable populations in Japan.
Tips for Strong Applications
A strong application should clearly explain the vaccination barrier and how the project will solve it.
Applicants should focus on:
- Clear target population
- Strong link to respiratory infectious disease prevention
- Practical vaccination environment improvement
- Evidence-based communication strategy
- Clear approach to vaccine hesitancy
- Strong collaboration where relevant
- Realistic implementation plan
- Defined project leadership
- Measurable outcomes
- Budget aligned with project activities
Applicants should show how the project will create practical improvements in vaccination access, communication, or delivery.
Common Mistakes to Avoid
Applicants should carefully check eligibility, project scope, and funding requirements.
Common mistakes include:
- Applying as an individual without an eligible organization
- Proposing work outside Japan
- Not focusing on older adults or high-risk individuals
- Submitting a project without a clear vaccination environment component
- Failing to connect the project to respiratory infectious diseases
- Providing vague communication or hesitancy activities
- Not identifying the Project Lead or responsible designee
- Including partners without clear roles
- Requesting more than 7,500,000 JPY
- Not showing how the requesting organization will maintain a key role
FAQ
What is this Pfizer grant about?
It supports healthcare improvement projects that strengthen vaccination environments to prevent respiratory infectious diseases among older adults and high-risk individuals in Japan.
How much funding can projects request?
Individual projects requesting up to 7,500,000 JPY will be considered.
Which diseases are included?
The program covers respiratory infectious diseases such as COVID-19, pneumococcal disease, and RSV infection.
Who can apply?
Eligible organizations in Japan may apply, including healthcare institutions, professional schools, professional organizations, government agencies, and other healthcare improvement entities.
Can organizations collaborate?
Yes. Collaborations within institutions, across departments, among professional teams, or between organizations are encouraged if all partners have relevant roles.
Can individuals apply directly?
Applicants must apply through an organization that can legally receive award funding directly from Pfizer International LLC.
What kinds of projects are supported?
Supported projects may improve vaccination access, risk communication, vaccine hesitancy communication, provider communication techniques, and vaccination approaches tailored to older adults and high-risk individuals.
Conclusion
Pfizer’s grant on improving the vaccination environment supports healthcare improvement initiatives that help older adults and high-risk individuals in Japan access vaccination against respiratory infectious diseases. With project funding of up to 7,500,000 JPY, the program encourages practical solutions that improve access, communication, confidence, and vaccination delivery.
Strong applications will demonstrate clear organizational eligibility, a focused healthcare improvement goal, practical vaccination environment strategies, strong project leadership, relevant collaboration, and measurable benefits for older adults and high-risk populations.
For more information, visit Pfizer.